Abstract

RAMIREZ-ORTIZ, Marco A. et al. Retinopathy of prematurity: controversies in the usage of intraocular antiangiogenics. Bol. Med. Hosp. Infant. Mex. [online]. 2013, vol.70, n.5, pp.344-350. ISSN 1665-1146.

The increase in survival rates among preterm infants, characteristics of neonatal care for such infants and a lack of suitable programs for preventing, detecting and treating retinopathy of prematurity (ROP) are factors that have made this disease the main cause of preventable blindness among children in Mexico. The advent of antiangiogenic agents in cancer treatment and their off-label use with favorable results in the treatment of proliferative vessel disease of the retina among adult patients, as well as anecdotal reports in the literature and a series of cases showing serious methodological flaws, have prompted their use in the treatment of retinopathy of prematurity. Unfortunately, these agents used indiscriminately in our country have a systemic absorption and secondary effects on the preterm patient's body. There are no long-term monitoring studies that guarantee their safe use in this segment of the population. This article describes the situation in our country and warns of the risks posed by the use of this type of drug on the preterm infant population.

Keywords : retinopathy of prematurity; antiangiogenics; intravitreal injections.

        · abstract in Spanish     · text in Spanish     · Spanish ( pdf )